ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

FDA has announced that the agency will begin immediately reviewing all new clinical trials that include shipping American citizens’ living cells to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients.

June 20, 2025

Vol.51 No.24

By Claire Marie Porter

In Brief

Peter Voorhees named associate director of clinical research at Wake Forest

Peter Voorhees was promoted to associate director of clinical research and will oversee clinical research for Atrium Health Wake Forest Baptist Comprehensive Cancer Center, as well as all processes related to clinical protocol and data management and protocol review and monitoring system.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC

FDA has approved Zusduri as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves tafasitamab-cxix for r/r follicular lymphoma

FDA has approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

June 20, 2025

Vol.51 No.24

ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

YOU MAY BE INTERESTED IN

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

Peter Voorhees named associate director of clinical research at Wake Forest

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC

FDA approves tafasitamab-cxix for r/r follicular lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login